Trial intelligence / Profile preview

Brexpiprazole adjunctive treatment in active adults with MDD

NCT02013609Phase 3Completed

Sponsor
Otsuka Pharmaceutical Development & Commercialization
Start
Nov 2013
Primary completion
Sep 2014
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2013; status: completed.

02

Drugs

brexpiprazole orally disintegrating tablet
03

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT02013609.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02013609.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call